Erlotinib Completed Phase 2 Trials for Cancer, Breast Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00109265A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy
NCT00054275Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
NCT00059852Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane
NCT00030537Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00633750Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery